(NASDAQ)

76.14

+0.22 (+0.29%)

After Hours: 76.80 +0.66 (+0.87%)

Volume (24h)	Market Cap.	Day Range	52w Range
4.31M	4.80B	76.04 - 83.95	14.01 - 99.95

Jan-15-21 05:45AM	Editas Medicine (EDIT) Gains As Market Dips: What You Should KnowZacks
Jan-14-21 03:11AM	With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting EdgeBarrons.com
Jan-12-21 01:24AM	Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301Zacks
Jan-11-21 12:20PM	Why Editas Medicine Stock Is Tumbling TodayMotley Fool
08:02AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex PharmaceuticalsZacks
Jan-11-21 06:05AM	Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare ConferenceGlobeNewswire
06:02AM	Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical TrialGlobeNewswire
Jan-11-21 06:00AM	Editas Medicine Announces Transition of Chief Scientific OfficerGlobeNewswire
Jan-08-21 09:01AM	CRISPR Gene Editing Stocks Up After Intellia's Pipeline UpdateZacks
Jan-07-21 04:24AM	Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily
02:33AM	Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily
Jan-07-21 08:42AM	3 Biotech Technological Developments to Watch Out For in 2021Zacks
Jan-06-21 11:00AM	A New Gene-Editing Technique May Be Able to Help Children Who Prematurely AgeBarrons.com
Jan-05-21 06:23AM	3 Biotech Stocks That Could Double Your Money in 2021Motley Fool
Jan-04-21 04:05AM	Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
09:27AM	5 Disruptive Biotech Stocks With Solid Long-Term PotentialZacks
Jan-04-21 06:09AM	3 Top Biotech Buyout Candidates in 2021Motley Fool
Dec-31-20 11:43AM	What Type Of Shareholders Own The Most Number of Editas Medicine, Inc. (NASDAQ:EDIT) Shares?Simply Wall St.
Dec-29-20 12:27PM	Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking TodayMotley Fool
Dec-24-20 11:10AM	Top ETF of December & Its Best StocksZacks
Dec-23-20 07:29AM	12 Best Genomic Stocks to Buy NowInsider Monkey
01:30AM	Stocks Showing Improved Relative Strength: Revance TherapeuticsInvestor's Business Daily
Dec-22-20 09:58AM	Return On Capital Employed Overview: Editas MedicineBenzinga
Dec-21-20 04:24AM	Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily
12:43PM	Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily
Dec-21-20 12:12PM	Why Editas Medicine Stock Is Skyrocketing TodayMotley Fool
Dec-17-20 04:05AM	Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of DirectorsGlobeNewswire
Dec-16-20 06:47AM	Is EDIT A Good Stock To Buy Now?Insider Monkey
07:35AM	3 Growth Stocks for In-the-Know InvestorsMotley Fool
Dec-14-20 01:58AM	Intra-Cellular Therapies Getting Closer To Key Technical BenchmarkInvestor's Business Daily
Dec-10-20 02:03AM	CRISPR Gene Editing: Owning the Future of MedicineZacks
12:47PM	Editas (EDIT) Submits Application to Start Study on EDIT-301Zacks
Dec-10-20 11:40AM	Why Editas Medicine Stock Is Skyrocketing for the Fourth Day in a RowMotley Fool
09:44AM	Looking Into Editas Medicine's Return On Capital EmployedBenzinga
Dec-10-20 07:42AM	The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference PresentationsBenzinga
Dec-09-20 04:01AM	Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDAGlobeNewswire
11:27AM	Why Editas Medicine Stock Is Rising for a Third Consecutive DayMotley Fool
Dec-09-20 11:06AM	Gene-Editing Stocks Skyrocket in $1.6 Billion Boom After DataBloomberg
Dec-08-20 03:41AM	Why Editas Medicine Stock Jumped Again TodayMotley Fool
Dec-07-20 11:41AM	Why Editas Medicine Stock Is Soaring TodayMotley Fool
Dec-05-20 11:32AM	Editas (EDIT) Up 9.3% Since Last Earnings Report: Can It Continue?Zacks
10:00AM	Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-ThalassemiaGlobeNewswire
Nov-10-20 04:01AM	Editas Medicine Reports Inducement Grants to New Chief Medical OfficerGlobeNewswire
05:41AM	Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Just Slashed Next Year's Revenue Estimates By 20%Simply Wall St.
Nov-09-20 04:05AM	Editas Medicine to Present at Barclays Gene Editing & Gene Therapy SummitGlobeNewswire
09:00AM	Editas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical OfficerGlobeNewswire
Nov-07-20 09:06AM	Editas Medicine, Inc. Beat Analyst Profit Forecasts, And Analysts Have New EstimatesSimply Wall St.
Nov-06-20 03:30AM	Editas Medicine, Inc. (EDIT) Q3 2020 Earnings Call TranscriptMotley Fool
11:24AM	Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in FocusZacks
Nov-05-20 05:25AM	Editas Medicine (EDIT) Tops Q3 Earnings and Revenue EstimatesZacks

Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine (EDIT) Stock Discussions on Social Media

- EDIT Stock on Twitter: https://twitter.com/search?q=$edit
- EDIT Stock on Reddit: https://www.reddit.com/search/?q=$edit
- EDIT Stock on SeekingAlpha: https://seekingalpha.com/symbol/EDIT

More Discussions

Mick · January 16, 2021

7 CRISPR Stocks for the Future of MedicineIf that sounds like a big deal, it’s because it is…For example, the following use-cases apply:Cure diseases like cystic fibrosis, cancer, and sickle cell disease. Create sustainable biofuels. Engineer more robust, pest- and disease-resistant crops. And much more. Indeed, the potential applications of CRISPR-Cas9 genetic editing systems are endless.In the CRISPR-Cas9 world, you have what I like to call the “Big 3” between CRISPR Therapeutics (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), and Intellia Therapeutics (NASDAQ:NTLA).

Upvote: 1 · Downvote: 1 · Replies: 0

etnispenga · January 15, 2021

Sponsored Post: Editas Medicine, Inc. announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another prospect. Check disclaimer in the landing page. Apparently, these other companies with mobile payments industry could be worth approx. $12.06 trillion by 2027. Here are some possible related articles you could check. http://b.link/PotentiallyTrillionWorthMarketResearch

Upvote: 31 · Downvote: 1 · Replies: 15

Thomas · January 15, 2021

I got to be serious: am I watching the same money flow from editas, crspr, ntla and beam just recirculating from one to the other every other day? I own some stake in all.

Upvote: 2 · Downvote: 1 · Replies: 7

Kevin · January 15, 2021

Does anyone know the % of BEAM that EDIT owns? I see this in the initial SEC filing but I don't know what that equates to.4.2 Equity Issuance. In partial consideration for the rights granted hereunder, on the date hereof, Beam shall issue to Editas (for no additional consideration), 1,833,333 shares of Series A-1 Preferred Stock and 1,222,222 shares of Series A-2 Preferred Stock (each as defined in the Stock Purchase Agreement), having an aggregate value, based on the price paid by Beam’s investors for such shares, of $3,666,666 (the “Beam Series A Shares” and such issuance, the “Initial Equity Issuance”).

Upvote: 2 · Downvote: 1 · Replies: 0

EDIT · January 15, 2021

We surpassed all our resistance points. Our last resistance point was at 78.64.

Upvote: 4 · Downvote: 0 · Replies: 0

EDIT · January 15, 2021

We are back in the ascending channel. Our support trendline is $77.50 right now. We could re test and if we hold we will be going back to the mid 90's in the next couple of days. Very good news for us today. Looks like we are out of detention for the moment. If we close in the mid 80's, look for us to make up some ground against the other crps stocks and get into the 100's by this time next week. Let's go !!!!!!

Upvote: 3 · Downvote: 0 · Replies: 0

Mick · January 15, 2021

1 million shares changing hands in half an hour.

Upvote: 4 · Downvote: 0 · Replies: 0

Mick · January 15, 2021

Congratulations to all that bought the dip this last week. Albright’s departure will make many rich. Easy money. Considering our fair value price should be $110 - $120 per share , more to come.

Upvote: 6 · Downvote: 0 · Replies: 0

Mick · January 15, 2021

Differences between Cpf1 and Cas9The guide RNA in CRISPR-Cas9 consists of a target-specific CRISPR RNA (crRNA) and an auxiliary trans-activating crRNA (tracrRNA), whereas CRISPR-Cpf1 arrays do not have this additional tracrRNA. Thus, the Cpf1 system needs only one RNA molecule to cut DNA instead of two.Feb 26, 2019

Upvote: 3 · Downvote: 0 · Replies: 0

Mick · January 15, 2021

With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting EdgeCrispr Therapeutics , Intellia Therapeutics , and Editas Medicine . The three gene-editing stocks have more than doubled in the past few months, reaching a total market value above $23 billion

Upvote: 1 · Downvote: 1 · Replies: 1

Mick · January 14, 2021

@Verb... have a read and let me know what you think. Advice From Three CSOsWhile conducting this analysis, there were three CSOs I interviewed in more depth – Anish Suri of Cue Biopharma, Charles Albright of Editas Medicine, and Nick Valiante of Glyde Bio. In these interviews, we discussed their career paths, their work as Chief Scientific Officers as well as advice they have for aspiring CSOsLikewise, Charles stressed the importance of portfolio focus as one of the most significant responsibilities of a CSO. Before coming onboard, Editas was spread thin with eight projects across five different tissues. Under his leadership, they’ve centered on ocular disease and ex vivo cell therapy as the leading programs for getting innovative medicines out the door – navigating the eye of the needle between taking on too many projects and being heavily reliant on too few.

Upvote: 3 · Downvote: 3 · Replies: 0

heidi · January 14, 2021

Anyone here who follows Jeff browns recommendations?

Upvote: 5 · Downvote: 1 · Replies: 0

EDIT · January 14, 2021

Charlies departure has reduced the stock price by $20. All other CRPS stocks have regained their previous levels they held before last weeks dump. We should be in the mid 90's right now absent Charlies departure. The good news is that it looks like the bottom is in for that correction. How we will regain those $20 per back is a mystery right now.

Upvote: 1 · Downvote: 3 · Replies: 0

Anonymous · January 14, 2021

Let’s be honest here, EDIT doesn’t need to say much, yes updates on dosing additional 101 patients and eventually dosing first 301 and 201 IND will all be great, but more votes of confidence from institutions like Ark will keep the positive momentum strong.

Upvote: 3 · Downvote: 1 · Replies: 2

Offer · January 14, 2021

We would like to welcome you on board on our flight to 100B valuation, we know you had other choices and we thank you for choosing the CRISPR Sector. Flight EDIT has a technical problem with the engine and will depart as soon as there is a new CSO. Special thanks go to our investors who are collecting dollars on this flight. Thanks again and see you at the destination.$EDIT $NTLA $CRSP $BEAM

Upvote: 5 · Downvote: 14 · Replies: 0

Gill · January 14, 2021

Edit got a price target raise to $86 from $69 at Wells Fargo.

Upvote: 7 · Downvote: 0 · Replies: 0

Michael · January 13, 2021

By the end of the week we know why Charlie left and the take over will be announced. Last FebROCHE completed the take over of SPARK for $4.3 billion. Coincidentally the market cap for EDIT is 4.6B! Edit has more patents and great pipeline, more than SPARK. The history will repeat itself!

Upvote: 1 · Downvote: 1 · Replies: 3

iamaverb · January 13, 2021

On 12/31/2020 short interest was 9,890,638 with a daily average vol of 3,352,724 shares traded, which is only 1 million shares less than the 10,888,953 shares sold short as reported on 12/15/2020. During the 15 day period ending on the 31st, Editas's share price rose and maintained a 40% to 50% average increase ($60 to 90's), after doubling in price ($30's to $60's) during the previous 15 day reporting period of 12.01 to 12.15. My point is..#$%$?... and why didn't more shorts rush to cover their positions during this dramatic rise in price? I thought for sure the increase in volume during those periods were the product of more short covering. Deep pockets for sure.

Upvote: 5 · Downvote: 1 · Replies: 0

iamaverb · January 13, 2021

I just got the chance to re-listen to the Q&A portion of the presentation that was cutoff for me earlier when the sound went dead, and I was quite pleased with how Lisa Michaels presented. A couple of takeaways were the 301 trials won't start until Q3 at the earliest and data may or may not be available for the all important ASH conference in Q4, ocular remains an important part of the company's future and I believe that we will see 102 beginning before 101 is finished, and that we should expect another capital raise sometime this year, probably at the time the company begins 301.

Upvote: 2 · Downvote: 0 · Replies: 0

EDIT · January 13, 2021

Collins said that they will present data for EDIT 101 at a scientific conference. Anyone know what conferences are scheduled to occur for 2021 that EDIT might be able to participate?

Upvote: 5 · Downvote: 1 · Replies: 0

Open in Yahoo | Open in Google | Open in Finviz